Moon Surgical
- Industry
- Medical Devices
- Founded Year
- 2019
- Headquarters
- 619 Old County Rd, San Carlos, California, 94070, United States
- Employee Count
- 17
Key People
- Anne Osdoit - CEO
- Fred Moll, M.D. - Independent Chair of the Board
- Antoine Papiernik - Board Member
- Mohamed Siddeek - Board Observer
- Steve Oesterle, M.D. - Board Observer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team includes experienced MedTech entrepreneurs and industry veterans.
The leadership team comprises individuals with extensive experience in the MedTech industry, including Fred Moll, a founder of Intuitive Surgical and Auris Health, and Anne Osdoit, CEO with a background in MedTech acceleration. Their combined expertise positions Moon Surgical favorably in the market.
- Clinical Need
-
Aspect: Very Strong
Summary: Maestro addresses a significant gap in laparoscopic procedures by providing robotic assistance.
The Maestro System is designed to support surgeons in soft tissue surgical procedures, offering robotic assistance that enhances precision and control. This addresses a critical need in the 18.8 million soft-tissue surgeries performed annually that are not currently supported by telerobotic systems.
- Competition
-
Aspect: Somewhat crowded
Summary: The surgical robotics market has established players, but Maestro offers unique features.
The surgical robotics market includes major players like Intuitive Surgical. However, Maestro's focus on adaptability and integration into existing workflows provides a unique value proposition that can differentiate it from competitors.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a robotic assistant that integrates seamlessly into existing surgical workflows presents moderate challenges.
The development of the Maestro System involves integrating advanced robotics into existing surgical procedures without disrupting workflows. While challenging, the company's progress and recent FDA clearance indicate a manageable technical path.
- Patent
-
Aspect: Applied
Summary: Moon Surgical has applied for patents to protect its technology.
The company has filed patent applications to protect its innovative robotic surgical assistant technology. Successful patent grants will provide a competitive edge and protect intellectual property.
- Financing
-
Aspect: Well-funded
Summary: Moon Surgical has secured significant funding from reputable investors.
With a recent $55.4 million funding round led by Sofinnova Partners and NVentures, and participation from Johnson & Johnson Innovation, GT Healthcare Capital, and Cathay Health, Moon Surgical is well-capitalized to advance its Maestro System towards commercialization.
- Regulatory
-
Aspect: 510k/PMA
Summary: Maestro has received FDA 510(k) clearance and CE mark approval.
The FDA 510(k) clearance obtained in December 2022 and the CE mark approval in April 2023 allow Moon Surgical to market the Maestro System in the U.S. and Europe, respectively, marking significant milestones in regulatory compliance.
Opportunity Rollup
- Odds of Success
- 3.6
- Peak Market Share
- 4.6
- Segment CAGR
- 10.7%
- Market Segment
- Surgical Robotics
- Market Sub Segment
- Laparoscopic Procedures
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.23 |
| 2 | 0.69 |
| 3 | 1.61 |
| 4 | 3.22 |
| 5 | 4.60 |
Key Takeaway
Moon Surgical's Maestro System addresses a significant clinical need in laparoscopic procedures, supported by a strong team and substantial funding, positioning it well in the growing surgical robotics market.